Arsenic trioxide (QTX-2101) vs Arsenic trioxide (SDK001)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Acute Myeloid Leukemia

Shared mechanism: PML-RARA fusion oncoprotein · full Acute Myeloid Leukemia pipeline

Arsenic trioxide (QTX-2101)

Developed by Quetzal Therapeutics

Phase 3 in Acute Myeloid Leukemiasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT07504458 (registry estimate)

No aligned efficacy figure on record for this race.

Arsenic trioxide (SDK001)

Developed by SDK Therapeutics

Phase 3 in Acute Myeloid Leukemiasmall molecule formulation
Partial signal

NCT06882031 · Phase 1 · completed

Treatment order was randomized and every participant received both the oral and intravenous formulations of the same active drug for direct comparison, but the study is open-label, very small, and measures only drug blood levels rather than a clinical outcome.

Next expected readout: June 2027 · NCT07296445 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Acute Myeloid Leukemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointArsenic trioxide (QTX-2101)Arsenic trioxide (SDK001)
OS, median—Trial running · NCT07504458—Trial running · NCT07296445
Complete remission—Trial running · NCT07504458—Trial running · NCT07296445
Event-free survival, median—Trial running · NCT07504458—Trial running · NCT07296445
Duration of response, median—Trial running · NCT07504458—Trial running · NCT07296445

OS, median

Arsenic trioxide (QTX-2101)
—Trial running · NCT07504458
Arsenic trioxide (SDK001)
—Trial running · NCT07296445

Complete remission

Arsenic trioxide (QTX-2101)
—Trial running · NCT07504458
Arsenic trioxide (SDK001)
—Trial running · NCT07296445

Event-free survival, median

Arsenic trioxide (QTX-2101)
—Trial running · NCT07504458
Arsenic trioxide (SDK001)
—Trial running · NCT07296445

Duration of response, median

Arsenic trioxide (QTX-2101)
—Trial running · NCT07504458
Arsenic trioxide (SDK001)
—Trial running · NCT07296445
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Arsenic trioxide (QTX-2101): no structured comparison results are available for Acute Myeloid Leukemia.

Arsenic trioxide (SDK001): no structured comparison results are available for Acute Myeloid Leukemia.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Arsenic trioxide (QTX-2101)'s landscape · Arsenic trioxide (SDK001)'s landscape